Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709754 | 0.85 | PSMB5 (0.44) | MAPTHSD17B10TP53ALDH1A1NPSR1 | |
| SCHEMBL3364540 | 0.83 | KMT2A (0.46) | MAPK1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL29502494 | 0.83 | KMT2A (0.46) | MAPK1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL1135252 | 0.82 | ALDH1A1 (0.48) | KMT2AMEN1CYP1A2HSD17B10CHEK1 | |
| SCHEMBL14677477 | 0.81 | KMT2A (0.47) | MAPTKMT2AMEN1CYP1A2HSD17B10 | |
| SCHEMBL22070548 | 0.81 | KMT2A (0.47) | MAPK1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL17115655 | 0.80 | PSMB5 (0.42) | NPSR1 | |
| SCHEMBL16877185 | 0.80 | KDM4E (0.46) | KMT2AMEN1HSD17B10ALDH1A1 | |
| SCHEMBL29756016 | 0.80 | KDM4E (0.46) | KMT2AMEN1HSD17B10ALDH1A1 | |
| SCHEMBL31638154 | 0.79 | MAPT (0.47) | MAPTKMT2AMEN1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | MAPK1 2617/4885MAPT 836/4885KMT2A 534/4885 |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | C1R, CBR1, HTR2C | MAPK1 2893/4885MAPT 883/4885KMT2A 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.